There are 2949 resources available
1310P - VinMetAtezo: Phase II trial of metronomic oral vinorelbine (MOV) with atezolizumab (ATZ) for recurrent stage IV NSCLC (GFPC*04-18)**
Presenter: Alain Vergnenegre
Session: E-Poster Display
Resources:
Abstract
1311P - First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA
Presenter: Thomas John
Session: E-Poster Display
Resources:
Abstract
1312P - Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis
Presenter: Marta Brambilla
Session: E-Poster Display
Resources:
Abstract
1313P - Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC
Presenter: Makoto Nishio
Session: E-Poster Display
Resources:
Abstract
1314P - Blood-based proteomic biomarkers for predicting response to immunotherapy in non-small cell lung cancer
Presenter: Yuval Shaked
Session: E-Poster Display
Resources:
Abstract
1315P - Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer)
Presenter: Enriqueta Felip
Session: E-Poster Display
Resources:
Abstract
1316P - Trial-based costs of all-cause adverse events in first-line therapy for advanced non-small cell lung cancer: Findings from CheckMate-9LA
Presenter: David Stenehjem
Session: E-Poster Display
Resources:
Abstract
1317P - Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting
Presenter: Remei Blanco
Session: E-Poster Display
Resources:
Abstract
1318P - Association between soluble PD-L1 and prognosis of non-small cell lung cancer (NSCLC) patients treated with immunotherapy
Presenter: Chiara Dellepiane
Session: E-Poster Display
Resources:
Abstract
1319P - Interdependence of KRAS and TP53 mutations in predicting benefit from immune checkpoint inhibitor (ICI) in non-squamous NSCLC
Presenter: Xiaoyan Li
Session: E-Poster Display
Resources:
Abstract